- Home
- PHAT vs GHI Comparison
PHAT vs GHI Comparison
Compare PHAT & GHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- GHI
- Stock Information
- Founded
- PHAT 2018
- GHI 1998
- Country
- PHAT United States
- GHI United States
- Employees
- PHAT N/A
- GHI N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- GHI Finance: Consumer Services
- Sector
- PHAT Health Care
- GHI Finance
- Exchange
- PHAT Nasdaq
- GHI Nasdaq
- Market Cap
- PHAT 339.8M
- GHI 285.3M
- IPO Year
- PHAT 2019
- GHI N/A
- Fundamental
- Price
- PHAT $3.96
- GHI $11.34
- Analyst Decision
- PHAT Strong Buy
- GHI Strong Buy
- Analyst Count
- PHAT 5
- GHI 4
- Target Price
- PHAT $22.50
- GHI $16.38
- AVG Volume (30 Days)
- PHAT 1.2M
- GHI 46.4K
- Earning Date
- PHAT 05-08-2025
- GHI 05-07-2025
- Dividend Yield
- PHAT N/A
- GHI 12.89%
- EPS Growth
- PHAT N/A
- GHI N/A
- EPS
- PHAT N/A
- GHI 0.76
- Revenue
- PHAT $55,252,000.00
- GHI $32,275,700.00
- Revenue This Year
- PHAT $202.23
- GHI $224.89
- Revenue Next Year
- PHAT $113.81
- GHI N/A
- P/E Ratio
- PHAT N/A
- GHI $15.11
- Revenue Growth
- PHAT 8001.47
- GHI N/A
- 52 Week Low
- PHAT $3.81
- GHI $10.12
- 52 Week High
- PHAT $19.71
- GHI $15.90
- Technical
- Relative Strength Index (RSI)
- PHAT 37.83
- GHI 39.35
- Support Level
- PHAT $3.87
- GHI $11.17
- Resistance Level
- PHAT $5.09
- GHI $11.48
- Average True Range (ATR)
- PHAT 0.59
- GHI 0.46
- MACD
- PHAT -0.10
- GHI -0.01
- Stochastic Oscillator
- PHAT 6.12
- GHI 41.62
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.